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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: End-stage renal disease (ESRD) is an important complication arising after
heart transplantation. At least 3e10% of recipients reach ESRD within 10 years after trans-
plant. The incidence of ESRD in Chinese recipients has not been reported. Here we sought
to assess the incidence, prognosis, and risk factors for ESRD in Chinese recipients.
Methods: We conducted a retrospective analysis of 248 heart recipients who survived >1 year
from 1998 through 2007. ESRD was defined as the requirement of maintenance dialysis.
Results: Renal dysfunction was present in 20 patients (8%) prior to transplant. With a follow-up
duration of 5.8  3.9 years, 30 patients developed ESRD. The cumulative incidence of ESRD
after heart transplantation was 2.1%  0.9%, 6.5%  1.8%, 16.8%  3.3%, and 36.5%  9.5%
at 2, 5, 10, and 15 years after transplant, respectively. Median onset of ESRD was 6.9 years
after transplant. Actuarial survival after dialysis was 74.8%  8.3%, 66.6%  9.2%, and
43.6%  12.6% at 1, 2, and 5 years, respectively. Independent risk factors for ESRD included
pretransplant serum creatinine (hazard ratio, 1.84; p Z 0.001), presence of diabetes prior
to transplant (hazard ratio, 2.51; p Z 0.017), and old age at transplant (hazard ratio, 1.05;
p Z 0.008).
Conclusion: There was a high incidence of ESRD in Chinese heart recipients. Patients with ESRD
had poor prognosis after dialysis.
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Chronic kidney disease and end-stage renal disease (ESRD)
are the important complications developing after heart
transplantation. They are associated with significant
mortality and morbidity.1e3 The cumulative 5-year risk of& Formosan Medical Association. All rights reserved.
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11e59%. With longer patient follow-up after heart trans-
plantation, ESRD becomes an increasingly important prob-
lem.1e3 At least 3e10% of heart transplant recipients reach
ESRD requiring renal replacement therapy within 10 years
after transplant.3 Risk factors for the development of
chronic kidney disease in heart transplant recipients are
well established.4e10 However, our understanding of ESRD
and outcomes after dialysis in heart recipients is limited.
Only a few studies have focused on heart recipients once
they have ESRD.11e19
In Asia, the first clinical heart transplantation was per-
formed by Wada in 1968. Because of poor result, no active
heart transplant program was performed for almost two
decades. In July 1987, the first heart transplantation was
started in Taiwan.20 Although Taiwan is a small island with
a population of 23 million, most of the heart trans-
plantations performed in Chinese population has been
performed in Taiwan.20 Taiwan has the highest incidence
and prevalence rates of ESRD in the world.21 ESRD devel-
oping after heart transplantation is an emerging problem.
We have published a preliminary result previously.22
However, the cumulative incidence, risk factors, and
prognosis of ESRD in Chinese heart transplant recipients
have not been reported properly. Here, we sought to assess
the incidence, risk factor, and prognosis of ESRD in Chinese
heart transplant recipients.
Patients and methods
Patients
We conducted a retrospective cohort study of all consecu-
tive patients who underwent heart transplantation at the
National Taiwan University Hospital from June 1989 to July
2007. After excluding 11 patients who underwent simulta-
neous heart and kidney transplantation and 54 patients who
survived <1 year, the remaining 248 patients comprised the
study group. This study has been approved by our institu-
tional ethics committee.
Immunosuppression
All patients received triple-drug immunosuppressive
therapy according to our previously reported heart trans-
plant protocol.23 Since 1995, we have used rabbit antithy-
mocyte globulins for induction therapy. Azathioprine
(4 mg/kg) was given 1 hour prior to the operation. Sol-
umedrol (1000 mg) was infused upon release of the aortic
cross-clamp. Rabbit antithymocyte globulin 1.5e2.5 mg/
kg/d was given after transplantation, for 3e5 days. Cyclo-
sporine was started orally within 5 days after trans-
plantation or after the recovery of renal function.
Cyclosporine dose was adjusted according to renal function
and serum cyclosporine level, which was maintained at the
trough level of 300e500 ng/mL during the first 3 months
after transplantation and at 200e300 ng/mL 1 year after
transplantation. Azathioprine was given at a dose of
1e2 mg/kg/d after transplantation, with the dose being
adjusted to maintain a white blood cell count of
4000e6000/mm3. Prednisone (0.5 mg/kg/d) was started onthe 2nd postoperative day and tapered to 0.2 mg/kg/d by
the 1st month after transplantation. Tacrolimus (FK-506)
and mycophenolate mofetil (Cellcept) were used for
recurrent rejection or severe adverse reactions to cyclo-
sporine and azathioprine. Since 2004, we started to use
mycophenolate mofetil for primary immunosuppression
instead of azathioprine. To reduce nephrotoxicity, cyclo-
sporine dose was decreased to maintain a serum trough
level of 250e350 ng/mL during the first 3 months after
transplantation and of 150e250 ng/mL 1 year after
transplantation.
Management
Endomyocardial biopsy was performed weekly in the first
month after transplantation, biweekly in the second
month, then monthly up to 6 months, and yearly thereafter.
For those patients surviving for more than 6 months after
transplantation, coronary angiography was performed
annually for surveillance of cardiac allograft vasculopathy.
All patients were followed monthly at a special cardiac
transplantation clinic. Standard chest roentgenogram,
blood tests, electrocardiogram, and physical examinations
were routinely performed at regular intervals.
Data were collected by retrospective chart review.
Pretransplant data included age, sex, diagnoses of heart
disease, body weight, body height, blood pressure, and
laboratory data. We estimated glomerular filtration rate
(eGFR) using CockcrofteGault formula, as suggested by the
National Kidney Foundation guidelines. Patients were
classified into five risk groups according to their eGFR
levels, and the cut points were selected on the basis of
published guidelines. Perioperative data included donor
age, donor weight, and allograft ischemic time. Post-
transplant data included mortality, date and cause of
death, date of first dialysis, and major complications. ESRD
was defined as the requirement of maintenance dialysis.
None of our patients underwent kidney transplantation
after heart transplantation because of ESRD. Diagnosis of
renal disease was made without renal biopsy, and some
patients had more than one etiology of ESRD.
Statistical analysis
Results are expressed as median with a range for contin-
uous variables or as frequencies for categorical variables.
Univariate risk factor analysis was performed using chi-
square test, Fisher exact test, and ManneWhitney test. Cox
regression was used to identify independent risk factors for
ESRD. The cumulative incidence of post-transplant ESRD
and actuarial survival curves were plotted according to the
KaplaneMeier method.
Results
Patients
The study cohort included 248 patients (41 women and 207
men). The median age at transplantation was 47.1 (range,
0.5e71) years. Diabetes mellitus was present in 48 patients
ESRD after HTX in Chinese patients 13(19%) prior to transplantation. The underlying cause of
heart failure was ischemic cardiomyopathy in 66 patients
(27%), dilated cardiomyopathy in 144 patients (58%), and
others in 38 patients. Previous cardiac operation was
present in 60 patients (24%). Median pretransplant serum
blood urea nitrogen was 23 (range, 1e113.6) mg/dL, serum
creatinine 1.1 (range, 0.4e6) mg/dL, and estimated GFR
71.02 (range, 12.42e176) mL/min/1.73 m2.End-stage renal disease
Renal dysfunction with serum creatinine >2.0 mg/dL was
present in 20 patients (8%) prior to transplant. The cumu-
lative incidence of ESRD after heart transplantation was 0%,
2.1%  0.9%, 6.5%  1.8%, 16.8%  3.3%, and 36.5%  9.5%
at 1, 2, 5, 10, and 15 years after transplant, respectively.
The median onset time of ESRD was 6.9 (range, 1.2e13.9)
years after transplant. The actuarial survival rate after
dialysis in ESRD patients was 74.8%  8.3%, 66.6%  9.2%,
and 43.6%  12.6% at 1, 2, and 5 years, respectively.Table 1 Comparison of patient characteristics between heart tr
Fisher exact test and ManneWhitney U test.
Variables With ESR
Age at operation (y) 54.2 (2
Male sex 28 (9
Blood type: identical 21 (7
Underlying heart disease
Ischemic cardiomyopathy 11 (3
Dilated cardiomyopathy 14 (4
Others 5 (6
Previous cardiac operation 8 (2
IABP at transplant 2 (7
ECMO at transplant 0 (0
Mechanical ventilation 0 (0
UNOS status I 11 (3
Presence of diabetes prior to transplant 13 (4
Pretransplant serum albumin (g/dL) 3.75 (2
Pretransplant serum bilirubin (mg/dL) 1.1 (0
Pretransplant serum BUN (mg/dL) 29.5 (1
Pretransplant serum creatinine (mg/dL) 1.4 (0
Pretransplant estimated GFR (mL/min/1.73 m2) 57.7 (1
90 1 (3
60e89 13 (4
30e59 13 (4
15e29 2 (6
14 1 (3
Positive CMV antibody prior to transplant 29 (9
Positive EBV antibody prior to transplant 30 (1
Positive HBV surface antigen 3 (1
Positive HCV antibody prior to transplant 2 (7
Donor age (y) 27.5 (1
Donor male sex 23 (7
Allograft ischemic time (min) 141.5 (4
Cardiopulmonary bypass time (min) 151.5 (7
BUN Z blood urea nitrogen; CMV Z cytomegalovirus; EBV Z Epste
ESRD Z end-stage renal disease; HBV Z hepatitis B virus; HCV Z hep
Network for Organ Sharing.Risk factor analysis
Univariate risk factor analysis (Table 1) revealed that old age
at transplant; high pretransplant serum levels of blood urea
nitrogen, creatinine, and low estimated GFR; and presence
of diabetes prior to transplant were associated with the
development of ESRD after transplant. Cox regression anal-
ysis revealed that the independent risk factors for ESRD
included old age at transplant, pretransplant serum creati-
nine, and presence of diabetes prior to transplant (Table 2).
The cut point of age for the prediction of ESRD was per-
formed by receiver operating characteristic (ROC) curve
(Fig. 1). The area under curve was 0.698 (95% CI,
0.614e0.782). The cut point of 49.5 years old can predict
postoperative ESRD with 70% sensitivity and 60% specificity.
Comparison with Western series
Comparison of various studies with respect to patient
characteristics and incidence of ESRD after heartansplant recipients with and without ESRD after transplant by
D (n Z 30) Without ESRD (n Z 218) p
7e71) 45.3 (0.5e69) 0.0005
3%) 179 (82%) 0.187
0%) 152 (70%) 0.999
7%) 55 (25%) 0.191
7%) 130 (60%) 0.236
%) 33 (15%)
7%) 52 (24%) 0.820
%) 19 (9%) 0.999
%) 18 (8%) 0.140
%) 23 (11%) 0.087
7%) 87 (40%) 0.843
3%) 35 (16%) 0.001
.3e5) 3.8 (2.2e5.1) 0.5187
.2e34.8) 1.4 (0.1e16.3) 0.4037
4e76) 22.3 (1e113.6) 0.0068
.6e6) 1.1 (0.4e4.6) 0.0026
2.4e128) 74.75 (17.97e176) 0.004
.3%) 55 (25.2%)
3.3%) 90 (41.3%)
3.3%) 64 (29.4%)
.7%) 9 (4.1%)
.3%) 0 (0%)
7%) 197 (90%) 0.489
00%) 213 (98%) 0.999
0%) 17 (8%) 0.715
%) 11 (5%) 0.648
6e54) 31 (1e60) 0.4527
7%) 156 (72%) 0.667
8e330) 132 (40e336) 0.7120
2e293) 143.5 (73e420) 0.340
in-Barr virus; ECMO Z extracorporeal membrane oxygenation;
atitis C virus; IABP Z intra-aortic balloon pump; UNOS Z United
Table 2 Independent risk factors for ESRD after transplantation by Cox regression analysis.
Variables Hazard
ratio
Standard
error
p 95% confidence
interval
Age at transplant 1.05 0.02 0.008 1.01e.09
Pretransplant serum creatinine 1.84 0.35 0.001 1.27e.67
Presence of diabetes prior to transplant 2.51 0.97 0.017 1.17e.35
14 J.-W. Chen et al.transplantation is given in Table 3. Only those series pub-
lished in recent 10 years were considered for
comparison.11e19 The crude incidence of ESRD after heart
transplantation in Western series ranged from 2% to 8%. The
incidence of ESRD in this study was compared to Alam
et al’s11 series of Canada and Satchithananda et al’s16
series of United Kingdom because these three groups had
similar age at transplant and follow-up duration. In this
current series, the crude incidence of ESRD was higher than
in Alam et al’s series (12.1% vs. 3.9%, p < 0.001 by Fisher
exact test) and Satchithananda et al’s series (12.1% vs.
3.9%, pZ 0.001 by Fisher exact test). We also had a higher
cumulative incidence of ESRD than in Satchithananda et al’s
series at 5 years (6.5% vs. 3.0%, p Z 0.013 by Fisher exact
test) and 10 years (16.8% vs. 11%, pZ 0.016 by Fisher exact
test) after transplant.Discussion
End-stage renal disease
A number of studies have reported the incidence, etiology,
pathology, and clinical course of chronic renal disease after
heart transplantation.1e10 Many patients have markedFigure 1 ROC curve of age for prediction of endeterioration in renal function over the first 6 months to 1
year. ESRD is often a long-term complication, occurring
several years after transplant, and a higher cumulative risk
of ESRD has been reported in studies with a longer follow-
up duration. The current study demonstrated that there
was a high incidence of ESRD in Chinese heart transplant
recipients. By actuarial analysis, 16.8% of our patient pop-
ulation developed ESRD by the end of the 10-year follow-
up. Although the follow-up duration was short, the
current cohort of heart transplant patients starting dialysis
was larger than the ones of previously published series.11e19
In our series, the high incidence of ESRD after heart
transplantation is probably related to an environmental
factor. In Taiwan, nontransplant cases of ESRD requiring
dialysis have increased progressively over the last decades.
When compared to international data using United States
Renal Data System, ESRD incidence in Taiwan ranked first
and prevalence ranked second in the world.21,24 It is
considered to be related to the use of Chinese herbal drugs
or compound analgesics.24
Risk factors
The previously reported risk factors for chronic kidney
disease after heart transplantation include pretransplantd-stage renal disease after heart transplant.
Table 3 Comparison of studies reporting incidence of end-stage renal disease after heart transplantation in Chinese patients
(Hsu) and other Western series published after 1998.
Lead author Hsu Hornberger van Gelder Frimat Satchithananda Rubel Senechal Alam
Year of publication This study 1998 1998 1998 2002 2004 2004 2007
Country Taiwan USA Netherlands France UK USA France Canada
Data source Hospital Medicare Hospital Hospital Hospital Hospital Hospital Registry
Patient number 248 1963 304 241 697 370 1211 2709
Age (y) 44.2  16.4 54.5  9.8 NA 52.8 47  10.5 49.1  11.1 NA 45.5  16.3
Male 83% 85% NA NA 86% 78% NA 79.5%
DCM 58% NA NA 44% 43% 49% NA 40.4%
Follow-up (y) 5.8  3.9 NA 6.6 NA 5.25 1e10 13.3 5.6  4.9
Crude incidence (%) 12.1 2 8 6.6 5.8 5.7 2.7 3.9
Cumulative incidence
1 y 0% 0.37% NA NA NA NA NA NA
5 y 6.5% 1.5% NA NA 3% NA NA NA
10 y 16.8% NA NA NA 11% 20.3% NA NA
DCM Z dilated cardiomyopathy; NA Z not available.
ESRD after HTX in Chinese patients 15renal dysfunction, postoperative acute renal failure,
recipient age, presence of diabetes mellitus, hypertension,
dyslipidemia, smoking, hepatitis C infection, and treatment
with calcineurin inhibitors.4 However, there is little infor-
mation on risk factors for ESRD after heart transplantation.
It has been reported that preoperative renal dysfunction,
high mean cyclosporine trough level in the first 6 months,
and presence of diabetes mellitus are significant predictors
of ESRD after heart transplantation. However, in other
studies, these risk factors have not been proved to be
associated with the development of ESRD after heart
transplantation.11e19 Here, we further demonstrated that
pretransplant serum creatinine, presence of diabetes prior
to transplant, and age at transplant were the major risk
factors. These risk factors were similar to those for chronic
kidney disease reported in our previous study of Chinese
heart transplant recipients.22 Low dose of cyclosporine or
tacrolimus and new immunosuppressive agents such as
mammalian targets of rapamycin inhibitors should be
considered in recipients with old age, diabetes mellitus,
and impaired renal function prior to transplant.25Survival
In our study, the major cause of mortality for patients who
survived <1 year were sepsis (12/54), rejection (26/54),
and primary graft failure (7/54). We separate the patients
into two groups with preoperative eGFR 60 mL/min/1.73 m2
to compare the impact of chronic kidney disease (CKD) on
the mortality in the first year after heart transplantation.
The 1-year mortality rate was 12.6% for patients with
preoperative eGFR >60 mL/min/1.73 m2, and 25.2% for
patients with preoperative eGFR <60 mL/min/1.73 m2
(p Z 0.005 by independent t test).
ESRD is associated with a high mortality in the general
population. Survival rate of heart transplant recipients with
ESRD is at least as poor, and likely worse.11e19 Increased
cardiac-related deaths seemed to account for the
decreased survival in heart transplant recipients starting
dialysis. Without renal transplantation, the reportedsurvival rate at 1, 3, and 5 years after first dialysis was
60e70%, 40e50%, and 10e20%, respectively,11 or even
worse.18 In this study, we also found that heart trans-
plantation was associated with a poor outcome in Chinese
heart transplant recipients starting dialysis. Survival of
heart transplant recipients after dialysis of our cohort was
consistent with that of heart transplant recipients in
previously published studies.11e19 It is much inferior to the
cumulative survival rates for all dialysis patients in Taiwan
after initiation of dialysis, that is, 85.1%, 74.6%, and 53.7%
at 1, 2, and 5 years after dialysis, respectively.24
Study limitations
The major limitations of our study are small case number
and short follow-up duration. However, despite a high
incidence of ESRD in Chinese heart transplant recipients,
a cohort of 30 cases of ERSD patients after transplant
represents one of the largest previously reported series in
a single center. The high incidence of ESRD in our patients
enabled us to identify the significant risk factors clearly.
Newer immunosuppressive drugs, such as mammalian
target of rapamycin (mTOR) inhibitors, are less nephrotoxic
when compared with calcineurin inhibitors. In combination
with or replacing calcineurin inhibitors, these have been
proved to delay renal functional deterioration in solid organ
transplantation.26,27 The outcome of heart transplant
patients with CKD may also be different. In this cohort,
mTOR inhibitors were not used, and we applied mTOR
inhibitors in heart transplant after 2007. Multicenter
studies are still ongoing, and their outcomes will be
compared in the future.
Conclusion
There was a high incidence of ESRD in Chinese heart
transplant recipients. Patients with ESRD had poor prog-
nosis after dialysis. Pretransplant serum creatinine, pres-
ence of diabetes prior to transplant, and old age at
transplant were the major risk factors.
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